SpringerLink
Log in

The Problem of Protocol Driven Costs in Pharmacoeconomic Analysis

  • Leading Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

The increasing number of economic evaluations of healthcare interventions and of drug therapies in particular has been well documented. Surveys of the quality of studies have demonstrated that standards of conduct of such studies have not similarly increased. Concerns over the standards have led to increased calls that economic analyses be more closely linked to randomised controlled clinical trials (RCT). Seven potential threats to the external validity of results limit the generalisability of studies based on RCTs. One such threat is the existence of protocol driven costs.

There are two main types of protocol driven costs. Protocol prescribed costs arise as a result of resource use mandated by the clinical trial design. Protocol derived costs occur when increased clinical investigations mandated by trial protocols lead to atypical disease management. Methods to control for protocol driven costs within pharmacoeconomic study designs are available. Modelling studies can be based on data within clinical trials combined with observational data representing more typical resource use. The adoption of pragmatic clinical trial designs provide greater external validity though reduced internal validity. Refinements to explanatory clinical trials can also lead to reduced protocol driven costs.

The extent that current studies control for such costs is unclear due to the lack of transparency in the reporting of study methods. A review of published studies found little consideration of protocol driven costs although in several studies there was evidence of their existence. Future studies conducted alongside RCTs should explicitly address how the issue of protocol driven costs was handled within the study framework.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Backhouse ME Backhouse RJ Edey SA. Economic evaluationbibliography. Health Econ 1992; 1 Suppl.: 1–235

    Google Scholar 

  2. Elixhauser A, Luce BR, Taylor WR, et al. Health care CBA/CEA:an update on the growth and composition of the literature.Med Care 1993; 31: JS1–11

    CAS  Google Scholar 

  3. Coyle D, Drummond MF. Does expenditure on pharmaceuticalsgood value for money? Current evidence and policy implications.Health Policy 1993; 26 (1): 55–75

    Article  PubMed  CAS  Google Scholar 

  4. Hillman AL, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies . N Engl J Med 1991; 324 1362–5

    Article  PubMed  CAS  Google Scholar 

  5. Commonwealth of Australia. Guidelines for the pharmaceuticalindustry on preparation of submissions to the PharmaceuticalBenefits Advisory Committee, including major submissionsinvolving economic analyses. Canberra: Australian GovernmentPublishing Press, 1995

  6. Fayers PM Hand DJ. Generalisation from phase III clinicaltrials: survival, quality of life and health economics. Lancet1997; 350: 1025–7

    CAS  Google Scholar 

  7. O’Brien B. Economic evaluation of pharmaceuticals.Frankenstein’s monster or vampire of trials? Med Care 1996;34 (12 Suppl.): DS99–108

    PubMed  Google Scholar 

  8. CCOHTA guidelines for economic evaluation of pharmaceuticals.2nd ed. Ottawa: CCOHTA, 1997

  9. Haycox A, Drummond M, Walley T. Pharmacoeconomics: integratingeconomic evaluation into clinical trials. Br J ClinPharmacol 1997; 43(6): 559–62

    Article  PubMed  CAS  Google Scholar 

  10. Kirchner V. Clinical studies to assess the economic impact ofnew therapies: pragmatic approaches to measuring costs. Anticancer Drugs 1993; Suppl. 3: 13–20

    Article  PubMed  Google Scholar 

  11. Adams ME McCall NT Gray DT, et al. Economic analysis inrandomised control trials. Med Care 1991; 30: 231–43

    Article  Google Scholar 

  12. Coyle D Davies LN Drummond MF. Trials and tribulations:emerging issues in the design of economic evaluations alongsideclinical trials. Int J Technol Assess Health Care 1998; 14:135–44

    Article  PubMed  CAS  Google Scholar 

  13. Drummond MF Davies L. Economic analysis alongside clinicaltrials: revisiting the methodological issues. Int J Technol AssessHealth Care 1991; 7(4): 561–73

    Article  PubMed  CAS  Google Scholar 

  14. Glick H. Strategies for economic assessment during the developmentof new drugs. Drug Inf J 1995; 29: 1391–403ai]

    Google Scholar 

  15. Mauskopf J Schulman K Bell l, et al. A strategy for collectingpharmacoeconomic data during phase II/III clinical trials.Pharmacoeconomics 1996; 9(3): 264–77

    Article  PubMed  CAS  Google Scholar 

  16. Powe NR Griffiths RI. The clinical-economic trial: promises,problems and challenges. Control Clin Trials 1995; 16: 377–94

    Article  PubMed  CAS  Google Scholar 

  17. Freemantle N Drummond M. Should clinical trials with concurrenteconomic analysis be blinded. JAMA 1977; 277: 63–4

    Article  Google Scholar 

  18. Rittenhouse BE. Exorcising protocol-induced spirits: makingthe clinical trial relevant for economics. Med Decis Making1997; 17(3): 331–9

    Article  PubMed  CAS  Google Scholar 

  19. Drummond MF, O’Brien B, Stoddart GL, et al. Methods for theeconomic evaluation of health care programmes. Oxford: OxfordUniversity Press, 1998

  20. Freund DA Dittus RS. Double-blind, placebo-controlled trialof daunorubicin and cytarabine with or without recombinanthuman granulocyte colony-stimulating factor in elderly patientswith acute myeloid leukemia: economic evaluation withattention to inpatient and outpatient resource utilization. J Natl Cancer Inst Monogr 1995; 19: 37–40

    PubMed  Google Scholar 

  21. Buxton M Drummond MF van Hout BA, et al. Modelling ineconomic evaluation: an unavoidable fact of life. Health Econ1997; 6: 217–28

    Article  PubMed  CAS  Google Scholar 

  22. Hillman AL Bloom BS. Economic effects of prophylactic use antidepressant drugs [see comments]. J Clin Epidemiol 1995

    Google Scholar 

  23. Schwart D Lellouch J. Explanatory and pragmatic attitudes intherapeutic trials. J Chronic Dis 1967; 20: 637–48

    Article  Google Scholar 

  24. Simon G Wagner E Vonkorff M. Cost-effectiveness comparisonsusing ‘real world’ randomized trials: the case of new antidepressant drugs [see comments]. J Clin Epidemiol 1995;4(3): 363–73

    Article  Google Scholar 

  25. Bennett CL Armitage JL Buchner D, et al. Economic analysisin phase III clinical cancer trials. Cancer Invest 1994; 12(3):336–42 ai26._Drummond MF Coyle D. The role of pilot studies in the economicevaluation of health technologies. Int J Technol AssessHealth Care. In press

    Article  PubMed  CAS  Google Scholar 

  26. Franz MJ Splett PL Monk A, et al. Cost-effectiveness of medicalnutrition therapy provided by dietitians for persons withnon-insulin-dependent diabetes mellitus. J Am Diet Assoc1995; 95(9): 1018–24

    Article  PubMed  CAS  Google Scholar 

  27. Griffiths RI Anderson GF Powe NR, et al. Economic impactof immunisation against rotavirus gastroenteritis: evidencefrom a clinical trial. Arch Pediatr Adolesc Med 1995; 149(4):407–14

    Article  PubMed  CAS  Google Scholar 

  28. Hooton TM Winter C Tiu F, et al. Randomised comparativetrial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women. JAMA 1995; 273(1):41–5

    Article  PubMed  CAS  Google Scholar 

  29. Jensen LS Grunnet N, Hanberg-Sorensen F, et al. Cost-effectivenessof blood transfusion and white cell reduction in electivecolorectal surgery. Transfusion 1995; 35(9): 719–22

    Article  PubMed  CAS  Google Scholar 

  30. Keogh A, Spratt P, McCosker C, et al. Ketoconazole to reducethe need for cyclosporine after cardiac transplantation. N Engl J Med 1995; 333(10): 628–33

    Article  PubMed  CAS  Google Scholar 

  31. Mauskopf JA, Backhouse ME, Jones D, et al. Synthetic surfactantfor rescue treatment of respiratory distress syndrome inpremature infants weighing from 700 to 1350 grams: impacton hospital resource use and charges. J Pediatr 1995; 126(1):94–101

    Article  PubMed  CAS  Google Scholar 

  32. Nichol KL, Lind A, Margolis KL, et al. The effectiveness ofvaccination against influenza in healthy, working adults. NEngl J Med 1995; 333(14): 889–93

    Article  CAS  Google Scholar 

  33. Ohls RK Osborne KA Christensen RD. Efficacy and cost analysisof treating very low birth weight infants with erythropoietinduring their first two weeks of life: a randomised,placebo-controlled trial. J Pediatr 1995; 126(3): 421–6

    Article  PubMed  CAS  Google Scholar 

  34. Omoigui NA, Califf RM, Pieper K, et al. Peripheral vascular complications in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). J Am Coll Cardiol 1995; 26(4): 922–30

    Article  PubMed  CAS  Google Scholar 

  35. Orlinsky M Goldberg RM, Chan L, et al. Cost analysis of staplingversus suturing for skin closure. Am J Emerg Med 1995;13(1): 77–81

    Article  PubMed  CAS  Google Scholar 

  36. Oster G, Borok GM, Menzin J, et al. A randomised trial to assesseffectiveness and cost in clinical practice: rationale and designof the Cholesterol Reduction Intervention Study (CRIS).Control Clin Trials 1995; 16(1): 3–16

    Article  PubMed  CAS  Google Scholar 

  37. Rutten van Mölken MP, Van Doorslaer EK, Jansen MC, et al.Costs and effects of inhaled corticosteroids and bronchodilatorsin asthma and chronic obstructive pulmonary disease.Am J Respir Crit Care Med 1995; 151(4): 975–82

    PubMed  Google Scholar 

  38. Schrott HG, Stein EA, Dujovne CA, et al. Enhanced low-densitylipoprotein cholesterol reduction and cost-effectivenessby low-dose colestipol plus lovastatin combination therapy. Am J Cardiol 1995; 75(1): 34–9

    Article  PubMed  CAS  Google Scholar 

  39. Smith Jr GR, Rost K, Kashner TM. A trial of the effect of astandardised psychiatric consultation on health outcomes andcosts in somatizing patients. Arch Gen Psychiatry 1995; 52(3): 238–43

    Article  PubMed  Google Scholar 

  40. Uyl-de Groot CA, Hagenbeek A, Verdonck LF, et al. Costeffectivenessof ABMT in comparison with CHOP chemotherapyin patients with intermediate- and high-grademalignant non-Hodgkin’s lymphoma (NHL). Bone MarrowTransplant 1995; 16 (3): 463–70

    PubMed  CAS  Google Scholar 

  41. van Bergen PF, Jonker JJ van Hout BA, et al. Costs and effectsof long term oral anticoagulant treatment after myocardialnfarction. JAMA 1995; 273(12): 925–8

    Article  PubMed  Google Scholar 

  42. Drummond MF, Jefferson TO. Guidelines for authors and peerreviewers of economic submissions to the BMJ. BMJ 1996;313: 275–83

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Epidemiology Unit, Loeb Research Institute, Ottawa Civic Hospital, 1053 Carling Avenue, Ottawa, Ontario, K1Y 4E9, Canada

    Douglas Coyle & Karen M. Lee

  2. Departments of Medicine and Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada

    Douglas Coyle

Authors
  1. Douglas Coyle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen M. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Douglas Coyle.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Coyle, D., Lee, K.M. The Problem of Protocol Driven Costs in Pharmacoeconomic Analysis. Pharmacoeconomics 14, 357–363 (1998). https://doi.org/10.2165/00019053-199814040-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199814040-00003

Keywords

Search

Navigation